EW (EW) Stock Analysis
Verdict: HOLD
EW trades at a premium 49.6x P/E; 78% gross margins face headwinds from TAVR market deceleration and persistent insider selling.
Investment score: 54/100
Is EW Stock Worth Reviewing? AI Model Thesis
The AI model evaluates Edwards Lifesciences as a HOLD. A premium valuation of 49.6x P/E and insider selling balance out stellar 78% gross margins and $2.94B in cash reserves.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| ABT | 32.57 | 3.45 | 3.76 | 20.40 | — | 0.12 |
| ISRG | 45.78 | 7.91 | 12.97 | 31.15 | — | 0.28 |
| SYK | 27.99 | 4.35 | 4.04 | 18.54 | — | 0.14 |
| BSX | 17.71 | 2.60 | 3.11 | 13.62 | — | 0.17 |
| BDX | 55.37 | 2.07 | 2.43 | 17.13 | — | 0.05 |
Should You Buy or Sell EW Stock? Model Reasoning
The model views EW as a Hold due to valuation headwinds at a 49.6x trailing P/E versus medtech peers like ABT (32.6x) and SYK (28.0x). While 78% gross margins and $2.94B in cash provide a strong financial foundation, persistent insider selling (20 sells, 0 buys) and moderate long-term revenue growth guidance (+7.4% for 2027) cap short-term risk-adjusted return potential.
EW Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Consensus EPS targets of 3.39 USD in 2027 and 3.80 USD in 2028 are achieved through 10-12% organic revenue CAGR.","Gross margins remain resilient at or above 77.0% (TTM 78.0%).","TMTT revenue growth compensates for TAVR deceleration without eroding consolidated operating margins."]
EW Risk & Opportunity Analysis
Key Investment Risks
- TAVR Market Saturation and Competitive Pricing Pressure — Increased competition from Medtronic and Boston Scientific in transcatheter heart valves could compress gross margins below historical 78% levels and slow market share expansion.
- Premium Valuation Vulnerability — Trading at 49.6x trailing EPS, any miss against consensus growth expectations ($3.39 EPS estimated for 2027) could trigger sharp valuation multiple compression toward peer averages (28x-32x).
- Persistent Insider Divestment — Zero insider buys alongside 20 insider sell transactions over recent months signals limited management expectation for immediate upside catalysts.
- Regulatory and Clinical Trial Execution Bottlenecks — Delays in clinical trial readouts or adverse regulatory decisions for next-generation valve iterations could impact long-term EPS consensus trajectory ($4.20 target for 2029).
Growth Opportunities & Upside Drivers
- Transcatheter Mitral and Tricuspid Therapies (TMTT) Expansion — Commercial expansion of PASCAL and Evoque platforms diversifies revenue beyond aortic valves, addressing a multi-billion dollar under-penetrated structural heart market by 2027.
- Industry-Leading Gross Margins — Gross margins of 78.0% provide strong pricing power and generate sustained free cash flow ($1.34B in 2025) to fund internal R&D pipeline advancements.
- Resilient Balance Sheet and Net Cash Position — Holding $2.94B in cash against $705.4M total debt yields a net cash balance of $2.23B, enabling strategic bolt-on M&A or share repurchases without debt distress.
- Underpenetrated International TAVR Markets — Analyst estimates model revenue growth to $7.42B in 2027 and $8.20B in 2028, driven by expanding international procedure adoption in Japan and Europe.
EW Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About EW (EW)
Is EW stock a good investment?
The cached TradeMates AI model rates EW as HOLD with an investment score of 54/100. The AI model evaluates Edwards Lifesciences as a HOLD. A premium valuation of 49.6x P/E and insider selling balance out stellar 78% gross margins and $2.94B in cash reserves. This is algorithmic model output, not personal investment advice.
Does EW pay a dividend?
The cached stock data on this page does not show a positive dividend yield for EW. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does EW stock do?
Edwards Lifesciences is a pure-play structural heart medical technology provider that generates high-margin revenue through proprietary transcatheter and surgical valve replacement/repair systems sold directly to hospitals and specialized surgical centers.
What is EW stock's price target?
This cached page does not contain a precise model fair value for EW.
Is EW stock a buy?
The TradeMates model verdict for EW is HOLD with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.
Is EW a good dividend stock?
EW is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.